Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223

[1]  N. Hirmas,et al.  Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy , 2020, Medicine.

[2]  N. Aaronson,et al.  The EORTC QLQ‐C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the “Real‐World”: Results from the Population‐Based PROFILES Registry , 2019, The oncologist.

[3]  N. Lawrentschuk,et al.  Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. , 2020, European urology.

[4]  W. Zwart,et al.  A prospective observational registry evaluating clinical outcomes of Radium‐223 treatment in a nonstudy population , 2019, International journal of cancer.

[5]  Chen Yu,et al.  Focus on Cancer Pain at Home: A Prospective Study of Quality of Life and Its Influencing Factors on Patients , 2019, Journal of Cancer Therapy.

[6]  A. Farcomeni,et al.  No evidence of association between psychological distress and pain relief in patients with bone metastases from castration-resistant prostate cancer treated with 223Radium. , 2019, European journal of cancer care.

[7]  D M Parkin,et al.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods , 2018, International journal of cancer.

[8]  G. Duncan,et al.  Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancer. , 2018, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[9]  F. Saad,et al.  Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program , 2019, BMC Cancer.

[10]  G. Cicero,et al.  The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience , 2017, Oncology.

[11]  F. Saad,et al.  Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials , 2017, Prostate Cancer and Prostatic Diseases.

[12]  C. Parker,et al.  Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. , 2016, European urology.

[13]  M. Hjermstad,et al.  Characteristics of breakthrough cancer pain and its influence on quality of life in an international cohort of patients with cancer , 2016, BMJ Supportive & Palliative Care.

[14]  C. Parker,et al.  Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  P. Colloca,et al.  The Effects of Social Support on Health-Related Quality of Life of Patients with Metastatic Prostate Cancer , 2016, Journal of Cancer Education.

[16]  Mika Gissler,et al.  Web-Based Versus Traditional Paper Questionnaires: A Mixed-Mode Survey With a Nordic Perspective , 2013, Journal of medical Internet research.

[17]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[18]  M. Sinclair,et al.  Comparison of response rates and cost-effectiveness for a community-based survey: postal, internet and telephone modes with generic or personalised recruitment approaches , 2012, BMC Medical Research Methodology.

[19]  Y. M. van der Linden,et al.  Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. , 2012, International journal of radiation oncology, biology, physics.

[20]  E. Basch,et al.  The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations. , 2010, Pain medicine.

[21]  J. Nelson,et al.  Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[22]  Brooks C. Holtom,et al.  Survey response rate levels and trends in organizational research , 2008 .

[23]  David Cella,et al.  Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. , 2008, The journal of pain : official journal of the American Pain Society.

[24]  K. Pienta,et al.  Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. , 1997, Urology.

[25]  C. Cleeland,et al.  Pain assessment: global use of the Brief Pain Inventory. , 1994, Annals of the Academy of Medicine, Singapore.

[26]  J. Lynch.  Treatment of advanced prostate cancer. , 1993, The Journal of family practice.